Suppr超能文献

相似文献

1
tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity.
Oncoimmunology. 2015 May 26;4(11):e1047579. doi: 10.1080/2162402X.2015.1047579. eCollection 2015 Nov.
2
NK Cells Require Cell-Extrinsic and -Intrinsic TYK2 for Full Functionality in Tumor Surveillance and Antibacterial Immunity.
J Immunol. 2019 Mar 15;202(6):1724-1734. doi: 10.4049/jimmunol.1701649. Epub 2019 Feb 4.
3
Cell-type-specific requirement for TYK2 in murine immune cells under steady state and challenged conditions.
Cell Mol Life Sci. 2025 Mar 2;82(1):98. doi: 10.1007/s00018-025-05625-9.
4
TYK2 kinase activity is required for functional type I interferon responses in vivo.
PLoS One. 2012;7(6):e39141. doi: 10.1371/journal.pone.0039141. Epub 2012 Jun 18.
5
Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice.
Blood. 2002 Mar 15;99(6):2094-9. doi: 10.1182/blood.v99.6.2094.
6
Tyrosine kinase 2 is not limiting human antiviral type III interferon responses.
Eur J Immunol. 2016 Nov;46(11):2639-2649. doi: 10.1002/eji.201646519. Epub 2016 Oct 5.
7
Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways.
Front Immunol. 2024 Sep 30;15:1437512. doi: 10.3389/fimmu.2024.1437512. eCollection 2024.
8
Control of Leishmania major in the absence of Tyk2 kinase.
Eur J Immunol. 2004 Feb;34(2):519-29. doi: 10.1002/eji.200324465.
9
STAT1 Isoforms Differentially Regulate NK Cell Maturation and Anti-tumor Activity.
Front Immunol. 2020 Sep 11;11:2189. doi: 10.3389/fimmu.2020.02189. eCollection 2020.
10
Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance.
Cancer Res. 2009 Jan 1;69(1):203-11. doi: 10.1158/0008-5472.CAN-08-1705.

引用本文的文献

1
Cell-type-specific requirement for TYK2 in murine immune cells under steady state and challenged conditions.
Cell Mol Life Sci. 2025 Mar 2;82(1):98. doi: 10.1007/s00018-025-05625-9.
2
Lack of TYK2 signaling enhances host resistance to Candida albicans skin infection.
Nat Commun. 2024 Dec 3;15(1):10493. doi: 10.1038/s41467-024-54888-6.
3
Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors.
Curr Med Chem. 2024;31(20):2900-2920. doi: 10.2174/0929867330666230324163414.
4
Tyk2 is a tumor suppressor in colorectal cancer.
Oncoimmunology. 2022 Sep 26;11(1):2127271. doi: 10.1080/2162402X.2022.2127271. eCollection 2022.
5
TYK2 in Cancer Metastases: Genomic and Proteomic Discovery.
Cancers (Basel). 2021 Aug 19;13(16):4171. doi: 10.3390/cancers13164171.
6
From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases.
Front Genet. 2021 Jul 5;12:685280. doi: 10.3389/fgene.2021.685280. eCollection 2021.
8
TYK2 Variants in B-Acute Lymphoblastic Leukaemia.
Genes (Basel). 2020 Nov 28;11(12):1434. doi: 10.3390/genes11121434.
9
STAT1 Isoforms Differentially Regulate NK Cell Maturation and Anti-tumor Activity.
Front Immunol. 2020 Sep 11;11:2189. doi: 10.3389/fimmu.2020.02189. eCollection 2020.
10
Tyrosine Kinase 2 Signalling Drives Pathogenic T cells in Colitis.
J Crohns Colitis. 2021 Apr 6;15(4):617-630. doi: 10.1093/ecco-jcc/jjaa199.

本文引用的文献

1
A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders.
Blood. 2014 Dec 11;124(25):3768-71. doi: 10.1182/blood-2014-07-588434. Epub 2014 Oct 27.
2
Role of type I interferon receptor signaling on NK cell development and functions.
PLoS One. 2014 Oct 21;9(10):e111302. doi: 10.1371/journal.pone.0111302. eCollection 2014.
4
Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance.
Blood. 2014 Oct 9;124(15):2370-9. doi: 10.1182/blood-2014-03-564450. Epub 2014 Sep 2.
5
Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation.
Blood. 2014 Jul 17;124(3):403-11. doi: 10.1182/blood-2013-05-499707. Epub 2014 Jun 2.
6
NK cells gain higher IFN-γ competence during terminal differentiation.
Eur J Immunol. 2014 Jul;44(7):2074-84. doi: 10.1002/eji.201344072. Epub 2014 May 19.
8
Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance.
Transgenic Res. 2014 Jun;23(3):519-29. doi: 10.1007/s11248-014-9795-y. Epub 2014 Apr 3.
9
Therapeutic potential of tyrosine kinase 2 in autoimmunity.
Expert Opin Ther Targets. 2014 May;18(5):571-80. doi: 10.1517/14728222.2014.892925. Epub 2014 Mar 21.
10
Evaluation of WO2013125543, WO2013146963 and EP2634185: the first Tyk2 inhibitors from Takeda and Sareum.
Expert Opin Ther Pat. 2014 Mar;24(3):361-8. doi: 10.1517/13543776.2014.864637. Epub 2014 Jan 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验